EMD Millipore's new Drypour packaging system helps minimize caking of pharmaceutical raw materials.
EMD Millipore, the life-science division of Merck KGaA, has introduced the Drypour packaging system, which minimizes caking during transport and storage of hygroscopic salts used in pharmaceutical manufacturing. The system, which consists of a polyethylene drum with a tamper-evident seal, apolyethylene liner with integrated desiccant bags, and a breathable interior Tyvek liner, helps improve operational efficiency by reducing the time and effort needed to break up heavily caked raw materials, according to the company.
The drum and polyethylene liner prevent outside moisture from entering the product. Any water vapor in the product itself can permeate the interior, tear-resistant Tyvek liner, migrate into the outer polyethylene liner and be absorbed by the integrated desiccant. Unlike other packaging systems, the desiccant bags in the Drypour system are fixed to the perforated polyethylene liner, thus preventing contact with the product, so product quality is not compromised, according to the company. For maximum effect, the desiccant bags are mounted in varying places on the liner.
A range of the company's line of Emprove pharmaceutical raw materials is available in the Drypour packaging system. The Drypour system is available in 100-kilogram package sizes and can be moved with common handling devices. The system meets both European Pharmacopoeia and USP requirements.
Source: EMD Millipore
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.